Effect of myo-inositol and di-chiro inositol plus vitamin D supplementation during pregnancy on prevention of gestational diabetes: a multi-centric, prospective, randomized, double-blind clinical trial

Authors

  • Hema Divakar Divakar Specialty Hospital, Bangalore, Karnataka, India
  • Sheetal Joshi Divakar Specialty Hospital, Bangalore, Karnataka, India
  • Vidya Thobbi Alameen Medical College, Vijayapur, Karnataka, India
  • Shobha Bembalgi KIMS College, Hubli, Karnataka, India
  • Sanjay Gupte Gupte Hospital, Pune, Maharashtra, India
  • Vidya V. Bhat Radhakrishna Multispeciality Hospital and IVF Center, Bangalore, Karnataka, India
  • Rita Singh Divakar Specialty Hospital, Bangalore, Karnataka, India
  • Poorni Narayanan Divakar Specialty Hospital, Bangalore, Karnataka, India
  • Bhagyashri Kulkarni Divakar Specialty Hospital, Bangalore, Karnataka, India
  • Prachi Ahire Shield Healthcare Pvt Ltd, India
  • Divakar G. V. Divakar Specialty Hospital, Bangalore, Karnataka, India
  • Isaac Manyonda St Georges Healthcare NHS Trust, Croydon, United Kingdom

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20232718

Keywords:

Gestational diabetes,, DM, Myoinositol and D-chiro inositol, Prevalence, Vitamin D

Abstract

Background: Aim of study was to evaluate the impact of myoinositol and D-chiro inositol plus vitamin D supplementation on the prevention of gestational diabetes mellitus (GDM) in pregnant women.

Methods: In the multi-centric, prospective, randomised, double-blind clinical trial, either vitamin D alone (group I) or myoinositol and D-chiro inositol plus Vitamin D (group II) were administered to pregnant women from 12 weeks of gestation. The administration was continued until delivery to primigravids who were normoglycemic at 12 weeks of gestation and consented. From October 2018 to December 2019. A total of 1250 women were enrolled, and randomly allocated to either of the groups: 630 women in Group I and 620 in Group II. The allocation was blinded. The primary outcome was the rate of GDM as assessed by oral glucose tolerance test (OGTT) recommended by diabetes in pregnancy Study Group India (DIPSI), International Federation of Gynecology and Obstetrics (FIGO) and the Government of India, at first antenatal visit followed by at weeks 24 to 28 in both the groups.

Results: The rate of GDM was found more in group I as compared to group II treated with myoinositol and D-chiro Inositol plus vitamin D, but the difference was not statistically significant (5.08% in group I and 3.22% in group II).

Conclusions: In conclusion, an improved trend has been noticed in the reduction of the rate of GDM with myoinositol and D-chiro inositol plus vitamin D as compared to vitamin D alone. Myoinositol and D-chiro inositol plus vitamin D supplementation may be a good option for pregnant women to prevent the GDM occurrence especially in women having positive risk factors for GDM.

 

References

Ministry of Health and Family Welfare, New Concept Information Systems. Maternal and health division, diagnosis and management of gestational diabetes mellitus: technical and operational guidelines. 2018. Available at: https://nhm.gov.in/New_Updates_2018/NHM_Components/RMNCH_MH_Guidelines/GestationalDiabetes-Mellitus.pdf. Accessed on 20 May 2023.

(DIPSI) DiPsGI. Diagnosis and management of gestational diabetes mellitus, 2021. Available at: https://icogonline.org/wp-content/uploads/pdf/gcpr/gdm-dipsi-guidline.pdf. Accessed on 20 May 2023.

Bahl S, Dhabhai N, Taneja S, Mittal P, Dewan R, Kaur J, et al. Burden, risk factors and outcomes associated with gestational diabetes in a population-based cohort of pregnant women from North India. BMC Preg Childb. 2022;22(1):1-6.

Veeraswamy S, Divakar H, Gupte S, Datta M, Kapur A, Vijayam B. Need for testing glucose tolerance in the early weeks of pregnancy. Indian J Endocrinol Metab. 2016;20(1):43-6.

(FOGSI) FoOaGSoI. Gestational diabetes. newsletter of endocrinology committee FOGSI. 2021;17.

Thanawala U, Divakar H, Jain R, Agarwal MM. Negotiating gestational diabetes mellitus in india: a national approach. Medicina (Kaunas). 2021;57(9).

World Health Organization. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Available at: http://apps.who.int/iris/bit- stream/10665/85975/1/WHO_NMH_MND_13.2_eng.pdf. Accessed on 20 May 2023.

International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33(3):676-82.

Gilbert L, Gross J, Lanzi S, Quansah DY, Puder J, Horsch A. How diet, physical activity and psychosocial well-being interact in women with gestational diabetes mellitus: an integrative review. BMC Preg Childbirth. 2019;19(1):60.

Mpondo BC, Ernest A, Dee HE. Gestational diabetes mellitus: challenges in diagnosis and management. J Diabetes Metab Disord. 2015;14:42.

Heimark D, McAllister J, Larner J. Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J. 2014;61(2):111-7.

Larner J, Brautigan DL, Thorner MO. D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol Med. 2010;16(11-12):543-52.

Corrado F, D'Anna R, Di Vieste G, Giordano D, Pintaudi B, Santamaria A, et al. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diab Medi: J Brit Diabet Associa. 2011;28(8):972-5.

Vitagliano A, Saccone G, Cosmi E, Visentin S, Dessole F, Ambrosini G, et al. Inositol for the prevention of gestational diabetes: a systematic review and meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2019;299(1):55-68.

Sobota-Grzeszyk A, Kuzmicki M, Szamatowicz J. Myoinositol in the prevention of gestational diabetes mellitus: is it sensible? J Diabet Res. 2019;2019:3915253.

D'Anna R, Di Benedetto A, Scilipoti A, Santamaria A, Interdonato ML, Petrella E, et al. Myo-inositol supplementation for prevention of gestational diabetes in obese pregnant women: a randomized controlled trial. Obstet Gynecol. 2015;126(2):310-5.

D'Anna R, Scilipoti A, Giordano D, Caruso C, Cannata ML, Interdonato ML, et al. myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care. 2013;36(4):854-7.

Crawford TJ, Crowther CA, Alsweiler J, Brown J. Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes. Coch Data Syst Rev. 2015(12):CD011507.

D'Anna R, Corrado F, Loddo S, Gullo G, Giunta L, Di Benedetto A. Myoinositol plus alpha-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study. Sci Rep. 2021;11(1):8866.

Dwarkanath P, Vinotha P, Thomas T, Joseph S, Thomas A, Shirley G, et al. Relationship of early vitamin D concentrations and gestational diabetes mellitus in Indian pregnant women. Front Nutr. 2019;6:116.

Rudnicki PM, Molsted-Pedersen L. Effect of 1,25-dihydroxycholecalciferol on glucose metabolism in gestational diabetes mellitus. Diabetologia. 1997;40(1):40-4.

Palacios C, Trak-Fellermeier MA, Martinez RX, Lopez-Perez L, Lips P, Salisi JA, et al. Regimens of vitamin D supplementation for women during pregnancy. Coch Data Syst Rev. 2019;10:CD013446.

Karcaaltincaba D, Calis P, Ocal N, Ozek A, Altug Inan M, Bayram M. Prevalence of gestational diabetes mellitus evaluated by universal screening with a 75-g, 2-hour oral glucose tolerance test and IADPSG criteria. 2017;138(2):148-51.

Downloads

Published

2023-08-29

Issue

Section

Original Research Articles